Multiple endocrine neoplasia type 2 other imaging findings: Difference between revisions
Jump to navigation
Jump to search
(→PET) |
(Mahshid) |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
{{Multiple endocrine neoplasia type 2}} | {{Multiple endocrine neoplasia type 2}} | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
Other imaging studies for multiple endocrine neoplasia type 2 include fluoro-di-glucose-[[PET]], [18F]-fluorodopamine ([18F]DA) [[PET]], and 99mTc-sestamibi | Other imaging studies for multiple endocrine neoplasia type 2 include fluoro-di-glucose-[[PET]], [18F]-fluorodopamine ([18F]DA) [[PET]], and [[Tc-99m sestamibi scintigraphy|99mTc-sestamibi scintigraphy]]. | ||
==Other Imaging Studies== | ==Other Imaging Studies== | ||
===Medullary Thyroid Carcinoma=== | ===Medullary Thyroid Carcinoma=== | ||
* Radioactive [[iodine]]: | * Radioactive [[iodine]]: Lesions do not concentrate radioactive [[iodine]] since the [[tumor]] does not arise from [[thyroid]] follicular cells. | ||
* FDG-[[PET]]: | * FDG-[[PET]]: Avid uptake is seen.<ref name="Radiopaedia">{{cite web | title = Radiopedia 2015 Medullary throid carcinoma [Dr Matt A. Morgan and Dr Yuranga Weerakkody]| url = http://radiopaedia.org/articles/medullary-thyroid-cancer }}</ref> | ||
* Tl-201: It has been shown to concentrate Thallium-201<ref name="pmid2866591">{{cite journal| author=Talpos GB, Jackson CE, Froelich JW, Kambouris AA, Block MA, Tashjian AH| title=Localization of residual medullary thyroid cancer by thallium/technetium scintigraphy. | journal=Surgery | year= 1985 | volume= 98 | issue= 6 | pages= 1189-96 | pmid=2866591 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2866591 }} </ref> | * Tl-201: It has been shown to concentrate Thallium-201.<ref name="pmid2866591">{{cite journal| author=Talpos GB, Jackson CE, Froelich JW, Kambouris AA, Block MA, Tashjian AH| title=Localization of residual medullary thyroid cancer by thallium/technetium scintigraphy. | journal=Surgery | year= 1985 | volume= 98 | issue= 6 | pages= 1189-96 | pmid=2866591 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2866591 }} </ref> | ||
* I-123 MIBG (metaiodobenzylguanidine): 30% of medullary thyroid cancer show uptake if the [[thyroid]] is blocked with Lugol solution prior to the scan | * I-123 MIBG (metaiodobenzylguanidine): 30% of [[medullary thyroid cancer]] show uptake if the [[thyroid]] is blocked with [[Lugol's solution]] prior to the scan. | ||
===Pheochromocytoma=== | ===Pheochromocytoma=== | ||
* [18F]-fluorodopamine ([18F]DA) [[PET]] is the best imaging modality for [[pheochromocytoma]] | * [18F]-fluorodopamine ([18F]DA) [[PET]] is the best imaging modality for [[pheochromocytoma]]. | ||
====I-123 MIBG (metaiodobenzylguanidine)==== | ====I-123 MIBG (metaiodobenzylguanidine)==== | ||
* MIBG (123I- or 131I- metaiodobenzylguanidine) [[scintigraphy]] is another imaging modality for [[pheochromocytoma]] | * MIBG (123I- or 131I- metaiodobenzylguanidine) [[scintigraphy]] is another imaging modality for [[pheochromocytoma]]. | ||
====Octreotide (somatostatin) scans==== | ====Octreotide (somatostatin) scans==== | ||
* Over 70% of [[tumor]]s express [[somatostatin]] receptors. Imaging is obtained 4 hours (+/- 24/48 hours) after an [[intravenous infusion]]. Unfortunately the [[kidney]] also has [[somatostatin receptor]]s, as | * Over 70% of [[tumor]]s express [[somatostatin]] receptors. Imaging is obtained 4 hours (+/- 24/48 hours) after an [[intravenous infusion]]. Unfortunately the [[kidney]] also has [[somatostatin receptor]]s, as well as areas of [[inflammation]], [[mammary gland]]s, [[liver]], [[spleen]], [[bowel]], [[gallbladder]], [[thyroid gland]] and [[salivary gland]]s.<ref>{{cite book | last = Pacak | first = Karel | title = Pheochromocytoma diagnosis, localization, and treatment | publisher = Blackwell Pub | location = Malden, MA Oxford | year = 2007 | isbn = 1405149507 }}</ref> | ||
* [[Octreotide]] is usually labeled with either 111In-DTPA (Octreoscan) or (less commonly)123I-Tyr3-DTPA. | * [[Octreotide]] is usually labeled with either 111In-DTPA (Octreoscan) or (less commonly)123I-Tyr3-DTPA. | ||
====PET==== | ====PET==== | ||
* 18F Dopa [[PET]] is thought to be highly sensitive according to initial results.<ref name="pmid11818620">{{cite journal| author=Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I et al.| title=Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. | journal=Radiology | year= 2002 | volume= 222 | issue= 2 | pages= 507-12 | pmid=11818620 | doi=10.1148/radiol.2222010622 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11818620 }} </ref> | * 18F Dopa [[PET]] is thought to be highly sensitive according to initial results.<ref name="pmid11818620">{{cite journal| author=Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I et al.| title=Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. | journal=Radiology | year= 2002 | volume= 222 | issue= 2 | pages= 507-12 | pmid=11818620 | doi=10.1148/radiol.2222010622 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11818620 }} </ref> | ||
===Parathyroid Carcinoma=== | ===Parathyroid Carcinoma=== | ||
* 99mTc-sestamibi scintigraphy is a good imaging modality for [[hyperparathyroidism]]. | * [[Tc-99m sestamibi scintigraphy|99mTc-sestamibi scintigraphy]] is a good imaging modality for [[hyperparathyroidism]]. | ||
<gallery> | <gallery> | ||
Image:Nuclear medicine.jpg|Image courtesy of Dr Hani Al Salami<ref name=radio01>Image courtesy of Dr Hani Al Salami. [http://www.radiopaedia.org Radiopaedia] (original file[http://radiopaedia.org/cases/7932‘’here’’]).[http://radiopaedia.org/licence Creative Commons BY-SA-NC]</ref> | Image:Nuclear medicine.jpg|Image courtesy of Dr Hani Al Salami<ref name=radio01>Image courtesy of Dr Hani Al Salami. [http://www.radiopaedia.org Radiopaedia] (original file[http://radiopaedia.org/cases/7932‘’here’’]).[http://radiopaedia.org/licence Creative Commons BY-SA-NC]</ref> | ||
| Line 32: | Line 36: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Oncology]] | |||
[[Category:Diseases]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Radiology]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 02:47, 27 November 2017
|
Multiple endocrine neoplasia type 2 Microchapters |
|
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Multiple endocrine neoplasia type 2 other imaging findings On the Web |
|
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 other imaging findings |
|
FDA on Multiple endocrine neoplasia type 2 other imaging findings |
|
CDC on Multiple endocrine neoplasia type 2 other imaging findings |
|
Multiple endocrine neoplasia type 2 other imaging findings in the news |
|
Blogs on Multiple endocrine neoplasia type 2 other imaging findings |
|
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
|
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [4]
Overview
Other imaging studies for multiple endocrine neoplasia type 2 include fluoro-di-glucose-PET, [18F]-fluorodopamine ([18F]DA) PET, and 99mTc-sestamibi scintigraphy.
Other Imaging Studies
Medullary Thyroid Carcinoma
- Radioactive iodine: Lesions do not concentrate radioactive iodine since the tumor does not arise from thyroid follicular cells.
- FDG-PET: Avid uptake is seen.[1]
- Tl-201: It has been shown to concentrate Thallium-201.[2]
- I-123 MIBG (metaiodobenzylguanidine): 30% of medullary thyroid cancer show uptake if the thyroid is blocked with Lugol's solution prior to the scan.
Pheochromocytoma
- [18F]-fluorodopamine ([18F]DA) PET is the best imaging modality for pheochromocytoma.
I-123 MIBG (metaiodobenzylguanidine)
- MIBG (123I- or 131I- metaiodobenzylguanidine) scintigraphy is another imaging modality for pheochromocytoma.
Octreotide (somatostatin) scans
- Over 70% of tumors express somatostatin receptors. Imaging is obtained 4 hours (+/- 24/48 hours) after an intravenous infusion. Unfortunately the kidney also has somatostatin receptors, as well as areas of inflammation, mammary glands, liver, spleen, bowel, gallbladder, thyroid gland and salivary glands.[3]
- Octreotide is usually labeled with either 111In-DTPA (Octreoscan) or (less commonly)123I-Tyr3-DTPA.
PET
Parathyroid Carcinoma
- 99mTc-sestamibi scintigraphy is a good imaging modality for hyperparathyroidism.
![Image courtesy of Dr Hani Al Salami[5]](/index.php/File:Nuclear_medicine.jpg)
![Image courtesy of Dr Roberto Schubert[6]](/index.php/File:Nuclear_medicine_02.jpg)
References
- ↑ "Radiopedia 2015 Medullary throid carcinoma [Dr Matt A. Morgan and Dr Yuranga Weerakkody]".
- ↑ Talpos GB, Jackson CE, Froelich JW, Kambouris AA, Block MA, Tashjian AH (1985). "Localization of residual medullary thyroid cancer by thallium/technetium scintigraphy". Surgery. 98 (6): 1189–96. PMID 2866591.
- ↑ Pacak, Karel (2007). Pheochromocytoma diagnosis, localization, and treatment. Malden, MA Oxford: Blackwell Pub. ISBN 1405149507.
- ↑ Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I; et al. (2002). "Pheochromocytomas: detection with 18F DOPA whole body PET--initial results." Radiology. 222 (2): 507–12. doi:10.1148/radiol.2222010622. PMID 11818620.
- ↑ Image courtesy of Dr Hani Al Salami. Radiopaedia (original file[1]).Creative Commons BY-SA-NC
- ↑ Image courtesy of Dr Roberto Schubert. Radiopaedia (original file[2]).Creative Commons BY-SA-NC